c-Myc, a critical metabolic regulator80, is controlled by a dual-pronged mechanism downstream of growth factor signaling in GBM cells52,53, which may have significant implications for the resistance to PI3K, AKT, and mTOR-targeted therapies. This evidence concerns the gene AKT1 and glioblastoma.